Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients

Clopidogrel and aspirin are the most commonly used medications worldwide for dual antiplatelet therapy after percutaneous coronary intervention. However, clopidogrel hyporesponsiveness related to gene polymorphisms is a concern. Populations with higher degrees of genetic admixture may have increased...

Full description

Bibliographic Details
Main Authors: J.F.M. Marchini, M.R. Pinto, G.C. Novaes, A.V. Badran, R.B. Pavão, G.L. Figueiredo, I.M. Lago, M.O. Lima-Filho, D.C. Lemos, M. Tonani, C.M. Antloga, L. Oliveira, J.C. Lorenzi, J.A. Marin-Neto
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Platelet function tests
Single nucleotide polymorphism
Percutaneous coronary intervention
Aspirin
Clopidogrel
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000100702&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000100702&lng=en&tlng=en

Similar Items